Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for alleged violations of securities laws, specifically related to misleading statements about its clinical programs [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 5, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their endpoints compared to placebo or bisphosphonate control groups [2]. Group 2: Investor Participation - Shareholders who purchased MREO shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3].